Ascendis Pharma A/S has announced the Australian registration of SKYTROFA® (lonapegsomatropin) by the Therapeutic Goods Administration $(TGA)$ as a once-weekly injectable therapy for paediatric growth hormone deficiency. This approval is a significant milestone for Ascendis Pharma and its distribution partner, Specialised Therapeutics $(ST)$, marking the second endocrinology therapy registered in Australia by ST. SKYTROFA is designed to treat growth failure in children and adolescents aged 3 to 18 due to insufficient endogenous growth hormone secretion, aiming to improve not only stature but also address the physical and psychosocial impacts associated with the condition. This approval follows prior endorsements by the US FDA and the European Medicines Agency.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.